RISANKIZUMAB - Résultats de recherche

Union européenne - français - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppresseurs - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 150 mg lnjektionslösung in einer fertigspritze

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 150mg solution injectable en stylo prérempli

abbvie ag - risankizumabum - solution injectable en stylo prérempli - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 75 mg lnjektionslösung in einer fertigspritze

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml. tela cum: alcohol isopropylicus. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

skyrizi 360 mg injektionslösung in einer patrone für ein dosiergerät

abbvie ag - risankizumabum - injektionslösung in einer patrone für ein dosiergerät - risankizumabum 360 mg, natrii acetas trihydricus corresp. natrium 0.5 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 2.4 ml. - morbus crohn bei erwachsenen - biotechnologika